This is a routine governance filing with no immediate trading catalyst. Monitor future filings for actual equity grants under the expanded plan, which could indicate management's capital allocation priorities.
ALKS drugs
ALKS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 21 $36.79entry
- T+1 · 6mo ago 0.00%α −0.45% · $36.79
- T+5 · 6mo ago +14.03%α +12.18% · $41.95
- T+20 · 5mo ago +22.30%α +21.76% · $44.99
- T+60 · 3mo ago +34.93%α +30.90% · $49.64
Price Chart
How similar events traded
Executive Summary
Alkermes filed an 8-K reporting results of its 2026 annual meeting, where shareholders approved an amendment to the 2018 Stock Option and Incentive Plan to increase authorized shares by 5,900,000. All director nominees were elected, and non-binding advisory votes on executive compensation and auditor ratification passed.
Key Facts
- Shareholders approved an amendment to increase shares reserved under the 2018 Stock Option and Incentive Plan by 5,900,000.
- All nine director nominees were elected with large majorities (e.g., Shane M. Cooke: 135.5M for, 5.5M against).
- Say-on-pay vote passed with 139.2M for, 1.8M against.
- Ratification of PricewaterhouseCoopers as auditor passed with 146.2M for, 2.8M against.
- Board authority to allot shares and disapply pre-emption rights under Irish law were renewed.
Financial Impact
The 5.9M share increase represents approximately 3.5% dilution relative to the current share count, but no shares are issued immediately.
Risk Factors
- Potential future dilution from equity grants to employees and directors.
- No material financial or operational changes reported.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-232584 |
| Document: alks-20260520.htm | 0001193125-26-232584 |
| Document: 0001193125-26-232584-index-headers.html | 0001193125-26-232584 |
| Document: 0001193125-26-232584-index.html | 0001193125-26-232584 |
| Document: 0001193125-26-232584.txt | 0001193125-26-232584 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers